|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,017.90 INR | +0.94% |
|
+3.37% | +30.62% |
| 09/07 | India's Dr Reddy's says semaglutide shipping disruption to last until at least late October | RE |
| 09/07 | India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice | RE |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.14 | 9.52 | 10.69 | 12.17 | 7.25 | |||||
Return on Total Capital | 10.62 | 12.34 | 14.29 | 16.83 | 9.9 | |||||
Return On Equity % | 13.18 | 20.5 | 25.38 | 26.46 | 16.99 | |||||
Return on Common Equity | 13.18 | 20.5 | 25.38 | 26.46 | 27.08 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 71.3 | 71.57 | 74.96 | 75.9 | 75.76 | |||||
SG&A Margin | 18.2 | 17.72 | 18.8 | 19.72 | 19.54 | |||||
EBITDA Margin % | 28 | 29.13 | 30.99 | 31.92 | 32.17 | |||||
EBITA Margin % | 25.46 | 27 | 28.85 | 29.94 | 30.22 | |||||
EBIT Margin % | 20.8 | 22.25 | 23.98 | 25.41 | 24.6 | |||||
Income From Continuing Operations Margin % | 9.13 | 12.94 | 15.44 | 16.6 | 15.29 | |||||
Net Income Margin % | 9.13 | 12.94 | 15.44 | 16.6 | 15.48 | |||||
Net Avail. For Common Margin % | 9.13 | 12.94 | 15.44 | 16.6 | 15.48 | |||||
Normalized Net Income Margin | 12.49 | 11.76 | 13.16 | 14.54 | 13.2 | |||||
Levered Free Cash Flow Margin | 12 | 15.37 | 20.71 | 11.1 | 18.61 | |||||
Unlevered Free Cash Flow Margin | 13.86 | 17.53 | 22.76 | 12.47 | 20.33 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.63 | 0.68 | 0.71 | 0.77 | 0.47 | |||||
Fixed Assets Turnover | 2.48 | 2.87 | 3.05 | 3.11 | 3.04 | |||||
Receivables Turnover (Average Receivables) | 5.39 | 5.38 | 5.66 | 6.21 | 5.71 | |||||
Inventory Turnover (Average Inventory) | 0.95 | 1.17 | 1.19 | 1.15 | 1.19 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.2 | 0.98 | 1.03 | 1.19 | 1.13 | |||||
Quick Ratio | 0.56 | 0.54 | 0.59 | 0.62 | 0.72 | |||||
Operating Cash Flow to Current Liabilities | 0.41 | 0.43 | 0.6 | 0.55 | 0.36 | |||||
Days Sales Outstanding (Average Receivables) | 67.69 | 67.84 | 64.62 | 58.81 | 63.93 | |||||
Days Outstanding Inventory (Average Inventory) | 384.39 | 313.06 | 307.16 | 316.91 | 305.92 | |||||
Average Days Payable Outstanding | 307.12 | 244.54 | 252.07 | 234.84 | 191.32 | |||||
Cash Conversion Cycle (Average Days) | 144.96 | 136.36 | 119.71 | 140.88 | 178.53 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 69.02 | 87.36 | 58.92 | 42.81 | 85.45 | |||||
Total Debt / Total Capital | 40.83 | 46.63 | 37.07 | 29.98 | 46.08 | |||||
LT Debt/Equity | 36.29 | 41.13 | 24.33 | 17.62 | 67.34 | |||||
Long-Term Debt / Total Capital | 21.47 | 21.95 | 15.31 | 12.34 | 36.31 | |||||
Total Liabilities / Total Assets | 54.56 | 58.71 | 54.48 | 49.36 | 60.32 | |||||
EBIT / Interest Expense | 7 | 6.44 | 7.29 | 11.64 | 8.94 | |||||
EBITDA / Interest Expense | 9.54 | 8.5 | 9.49 | 14.72 | 11.81 | |||||
(EBITDA - Capex) / Interest Expense | 8.74 | 6.77 | 8.26 | 12.28 | 10.05 | |||||
Total Debt / EBITDA | 1.7 | 1.92 | 1.21 | 0.88 | 3.31 | |||||
Net Debt / EBITDA | 1.46 | 1.66 | 0.91 | 0.69 | 2.79 | |||||
Total Debt / (EBITDA - Capex) | 1.86 | 2.41 | 1.39 | 1.05 | 3.89 | |||||
Net Debt / (EBITDA - Capex) | 1.6 | 2.09 | 1.04 | 0.83 | 3.28 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 6.29 | 13.07 | 11.51 | 7.35 | 21.39 | |||||
Gross Profit, 1 Yr. Growth % | 3.55 | 13.5 | 16.8 | 8.69 | 21.18 | |||||
EBITDA, 1 Yr. Growth % | -1.92 | 17.64 | 18.63 | 10.55 | 22.33 | |||||
EBITA, 1 Yr. Growth % | -2.7 | 19.94 | 19.14 | 11.41 | 22.53 | |||||
EBIT, 1 Yr. Growth % | -2.93 | 20.95 | 20.2 | 13.75 | 17.55 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -37.92 | 60.22 | 33.02 | 15.39 | 11.87 | |||||
Net Income, 1 Yr. Growth % | -37.92 | 60.22 | 33.02 | 15.39 | 13.19 | |||||
Normalized Net Income, 1 Yr. Growth % | 12.54 | 6.46 | 24.75 | 18.6 | 10.22 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -37.92 | 60.22 | 33.02 | 15.39 | 13.19 | |||||
Accounts Receivable, 1 Yr. Growth % | 7.16 | 19.07 | -5.12 | 1.2 | 62.39 | |||||
Inventory, 1 Yr. Growth % | -8.16 | -9.45 | 2.22 | 11.5 | 23.49 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -10.48 | 6.56 | 3.41 | 6.85 | 40.36 | |||||
Total Assets, 1 Yr. Growth % | -6.93 | 14.6 | 0.32 | -0.47 | 195.62 | |||||
Tangible Book Value, 1 Yr. Growth % | 42.17 | -64.09 | 150.99 | 54.42 | -771.39 | |||||
Common Equity, 1 Yr. Growth % | 1.98 | 4.12 | 10.62 | 10.71 | 10.51 | |||||
Cash From Operations, 1 Yr. Growth % | -10.09 | 31.34 | 37.92 | -20.85 | 16.93 | |||||
Capital Expenditures, 1 Yr. Growth % | -39.56 | 183.33 | -24.6 | 41.38 | 10.71 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 28.1 | 44.8 | 50.25 | -42.43 | 103.43 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 16.02 | 43 | 44.82 | -41.2 | 97.91 | |||||
Dividend Per Share, 1 Yr. Growth % | -5.71 | 33.33 | 27.27 | 14.29 | 18.75 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 3.52 | 9.63 | 12.29 | 9.41 | 14.15 | |||||
Gross Profit, 2 Yr. CAGR % | 2.51 | 8.41 | 15.14 | 12.67 | 14.76 | |||||
EBITDA, 2 Yr. CAGR % | 6.06 | 7.42 | 18.14 | 14.52 | 16.29 | |||||
EBITA, 2 Yr. CAGR % | 6.3 | 8.02 | 19.54 | 15.21 | 16.83 | |||||
EBIT, 2 Yr. CAGR % | 7.93 | 8.35 | 20.58 | 16.93 | 15.63 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -12.91 | -0.27 | 45.99 | 23.89 | 13.62 | |||||
Net Income, 2 Yr. CAGR % | -12.91 | -0.27 | 45.99 | 23.89 | 14.28 | |||||
Normalized Net Income, 2 Yr. CAGR % | 21.07 | 9.46 | 15.24 | 21.64 | 14.33 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -12.91 | -0.27 | 45.99 | 23.89 | 14.28 | |||||
Accounts Receivable, 2 Yr. CAGR % | -0.51 | 12.96 | 6.29 | -2.01 | 28.19 | |||||
Inventory, 2 Yr. CAGR % | 7.06 | -8.81 | -3.79 | 6.76 | 17.34 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -4.09 | -2.33 | 4.97 | 5.12 | 22.47 | |||||
Total Assets, 2 Yr. CAGR % | -3.3 | 3.28 | 7.22 | -0.07 | 71.53 | |||||
Tangible Book Value, 2 Yr. CAGR % | 345.72 | -28.55 | -5.07 | 96.87 | 221.99 | |||||
Common Equity, 2 Yr. CAGR % | 11.1 | 3.04 | 7.32 | 10.67 | 10.61 | |||||
Cash From Operations, 2 Yr. CAGR % | 13.77 | 8.67 | 34.59 | 4.48 | -3.8 | |||||
Capital Expenditures, 2 Yr. CAGR % | -29.43 | 30.86 | 46.17 | 3.25 | 25.11 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 71.29 | 36.19 | 47.5 | -7 | 8.22 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 37 | 28.8 | 43.91 | -7.72 | 7.88 | |||||
Dividend Per Share, 2 Yr. CAGR % | 39.33 | 12.12 | 30.27 | 20.6 | 16.5 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 3.5 | 6.61 | 10.25 | 10.62 | 13.27 | |||||
Gross Profit, 3 Yr. CAGR % | 3.61 | 6.05 | 11.14 | 12.95 | 15.44 | |||||
EBITDA, 3 Yr. CAGR % | 6.7 | 9.79 | 11.03 | 15.55 | 17.07 | |||||
EBITA, 3 Yr. CAGR % | 7.03 | 10.66 | 11.61 | 16.76 | 17.6 | |||||
EBIT, 3 Yr. CAGR % | 8.94 | 12.11 | 12.17 | 18.26 | 17.14 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 21.22 | 6.71 | 9.78 | 34.98 | 19.75 | |||||
Net Income, 3 Yr. CAGR % | 21.22 | 6.71 | 9.78 | 34.98 | 20.22 | |||||
Normalized Net Income, 3 Yr. CAGR % | 24.44 | 15.99 | 14.34 | 16.35 | 17.71 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 21.22 | 6.71 | 9.78 | 34.98 | 20.22 | |||||
Accounts Receivable, 3 Yr. CAGR % | 4.37 | 5.63 | 6.58 | 4.57 | 15.96 | |||||
Inventory, 3 Yr. CAGR % | 8.36 | 1.25 | -5.27 | 1.06 | 12.07 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -0.34 | -0.67 | -0.46 | 5.59 | 15.75 | |||||
Total Assets, 3 Yr. CAGR % | -2.47 | 2.33 | 2.28 | 4.59 | 43.45 | |||||
Tangible Book Value, 3 Yr. CAGR % | 81.28 | 92.5 | 8.61 | 11.65 | 196.33 | |||||
Common Equity, 3 Yr. CAGR % | 8.01 | 8.72 | 5.51 | 8.44 | 10.61 | |||||
Cash From Operations, 3 Yr. CAGR % | 0.09 | 19.35 | 17.66 | 12.76 | 8.48 | |||||
Capital Expenditures, 3 Yr. CAGR % | -32.64 | 12.16 | 8.9 | 44.55 | 5.68 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 12.64 | 61.96 | 40.73 | 7.79 | 20.73 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 4.69 | 38.97 | 33.93 | 6.79 | 19.01 | |||||
Dividend Per Share, 3 Yr. CAGR % | 24.74 | 37.3 | 16.96 | 24.71 | 19.98 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 7.91 | 10.09 | 6.93 | 7.72 | 11.8 | |||||
Gross Profit, 5 Yr. CAGR % | 8.33 | 9.99 | 8.08 | 8.65 | 12.57 | |||||
EBITDA, 5 Yr. CAGR % | 11.58 | 15.84 | 11.13 | 11.66 | 13.11 | |||||
EBITA, 5 Yr. CAGR % | 11.73 | 17.09 | 11.87 | 12.46 | 13.67 | |||||
EBIT, 5 Yr. CAGR % | 10.3 | 17.58 | 13.45 | 14.01 | 13.54 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -3.6 | 12.92 | 30.58 | 13.28 | 11.3 | |||||
Net Income, 5 Yr. CAGR % | -3.6 | 12.92 | 30.58 | 13.28 | 11.56 | |||||
Normalized Net Income, 5 Yr. CAGR % | 10.6 | 15.26 | 20.67 | 18.22 | 14.34 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -3.6 | 12.92 | 30.58 | 13.28 | 11.56 | |||||
Accounts Receivable, 5 Yr. CAGR % | 11.42 | 9.17 | 5.14 | 2.5 | 14.75 | |||||
Inventory, 5 Yr. CAGR % | 9.57 | 2.55 | 3.33 | 3.42 | 3.2 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 6.82 | 4.03 | 1.75 | 1.61 | 8.15 | |||||
Total Assets, 5 Yr. CAGR % | 6.19 | 1.06 | 1.3 | 1.36 | 25.78 | |||||
Tangible Book Value, 5 Yr. CAGR % | -2.81 | -5.8 | 39.95 | 94.24 | 67.75 | |||||
Common Equity, 5 Yr. CAGR % | 6.47 | 6.04 | 7.73 | 9.49 | 7.52 | |||||
Cash From Operations, 5 Yr. CAGR % | 12.31 | 21.51 | 12.68 | 13.16 | 8.55 | |||||
Capital Expenditures, 5 Yr. CAGR % | -16.08 | -6.22 | -8.17 | 8.51 | 15.11 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 52.64 | 36.11 | 25.47 | 29.73 | 26.69 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 36.37 | 68 | 18.9 | 17.98 | 22.83 | |||||
Dividend Per Share, 5 Yr. CAGR % | 18.71 | 25.74 | 26.93 | 30.36 | 16.77 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















